Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development
26.11.2025 11:15:00 CET | Business Wire | Press release
Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments
Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/
Aerial shot of Wellington International (Photo: AETOSWire)
Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championship golf course located in Wellington, Florida – a global icon of equestrian sport. This investment marks Modon’s first direct investment in an equestrian led development in the United States, complementing its existing global portfolio, and reinforcing its strategy to partner with leading international organisations in expanding its presence across ultra-luxury destination developments. The partnership further strengthens Modon’s position as a globally recognised investor in large-scale, high-value real estate and lifestyle projects.
Through the investment, Modon joins WLP’s group of existing investors and operators to advance a multi-asset portfolio of lifestyle and sports destinations. The portfolio includes the world-renowned Wellington International showgrounds; The Wanderers Club, a private family-oriented country club offering golf, tennis, swimming and dining; The Wellington, a new private residential club community comprising 253 best-in-class residences set to open in 2028 and featuring a championship-level golf course designed by David McLay Kidd; and a planned lifestyle Marketplace featuring a luxury boutique hotel, residences, shops, offices and restaurants. Together, these assets form a long-term masterplan to strengthen Wellington’s position as the global home of equestrian sport and luxury living.
The investment also includes a strategic licence agreement enabling Modon to use Wellington International’s brand and intellectual property across several key strategic markets to support the development of future lifestyle and community destinations. As part of the agreement, Modon will also become a premier sponsor of the Winter Equestrian Festival and Adequan® Global Dressage Festival (AGDF) – the world’s largest and longest-running hunter/jumper and dressage competitions, attracting over 250,000 spectators and exhibitors each year.
His Excellency Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Modon Holding, said: “This strategic investment reflects Modon’s ambition to invest alongside world-class partners that share our vision for excellence in destination development. Wellington Lifestyle Partners represents a unique collaboration that brings together expertise in real estate, equestrian, hospitality and sports-led communities. By extending our reach to the United States, we are furthering Modon’s role in delivering sustainable destinations that embody quality, innovation and cultural connection.”
Bill O’Regan, Group Chief Executive Officer of Modon Holding, added: “Our partnership with Wellington Lifestyle Partners aligns with Modon’s strategy to develop integrated lifestyle destinations that combine community, sport and hospitality. Wellington International is recognised globally for its equestrian excellence, and this collaboration provides a valuable opportunity to exchange expertise in operations, master planning and design. It complements our portfolio across Hudayriyat Island, Ras El Hekma and La Zagaleta, reinforcing Modon’s commitment to delivering transformative, world-class destinations.”
Mark Bellissimo, Founder of Wellington Lifestyle Partners,said: “The addition of Modon Holding to Wellington Lifestyle Partners brings together an exceptional blend of expertise. With Modon’s world-class destination development experience, Doug McMahon and NEXUS’ leadership in luxury community development, and equestrian Murray Kessler as CEO of Wellington International, we are uniquely positioned to accelerate our vision to set a new standard of quality for an equestrian lifestyle destination here in Wellington.”
About Modon:
Modon is an international holding company, headquartered in Abu Dhabi, United Arab Emirates, and listed on the Abu Dhabi Securities Exchange (ADX). We are at the forefront of urban innovation, creating iconic designs and experiences that continually surpass expectations. Our primary business sectors include real estate, hospitality, asset management, investments, events, and tourism. Our goal is to deliver long-term, sustainable value, laying the foundations for intelligent, connected living.
About Wellington Lifestyle Partners
Based in Wellington, Wellington Lifestyle Partners (WLP) is backed by private investors, Mark Bellissimo, Lisa Lourie, Roger Smith, Jeff Skoll, Mike Smith and NEXUS Luxury Collection, and is a real estate, hospitality and sports management company dedicated to excellence. Led by Chief Executive Officer Douglas McMahon and President Paige Nuñez, WLP operates a portfolio that includes the new private residential club community of The Wellington, the Wellington International showgrounds, The Wanderers Club and a charming commercial Marketplace to include a luxury boutique hotel, residences, shops, offices and restaurants. WLP is committed to investing in Wellington for generations to come and supporting its position as the premier horse sport destination in the world. www.wlpfl.com
About Wellington International:
Established in 1974, Wellington International spans more than 200 acres in the heart of Wellington, Florida, and is renowned worldwide as a premier equestrian destination. Each year, it attracts riders and visitors from across all 50 U.S. states and more than 55 countries, hosting world-class competitions and events throughout the year. The venue combines state-of-the-art arenas and equestrian facilities with VIP hospitality, dining, and retail experiences, contributing more than $500 million annually in economic impact to the Palm Beach County economy through tourism, employment, and global investment.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20251125937208/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom